Uremic neuropathy …

Peripheral Neuropathies

Updated 01.12.2024
Released 11.15.1997
Expires For CME 01.12.2027

Uremic neuropathy

Authors: Yi Pan MD PhD, Florian P Thomas MD MA PhD MS

See Contributor Disclosures

Editor: Louis H Weimer MD

Uremic neuropathy

In This Article

Quick Link

Introduction

Overview

Chronic renal failure is one of the common causes for peripheral neuropathy. In this article, the authors summarize the clinical, electrophysiological, and pathological features of uremic neuropathy. Prevention and treatment of uremic neuropathy focus on dialysis and renal transplantation.

Key points

	• Uremic neuropathy is a distal sensorimotor polyneuropathy caused by uremic toxins.
	• Symptoms are insidious in onset. Paresthesias are usually the earliest symptoms; weakness and atrophy will follow the sensory symptoms.
	• The pathologic features are severe axonal degeneration in the most distal nerve trunks with secondary segmental demyelination.
	• Chronic dialysis may prevent neuropathy in some patients, especially if begun early. Renal transplantation is generally the most successful method to prevent neuropathy.

Historical note and terminology

Uremic neuropathy is a distal sensorimotor polyneuropathy caused by uremic toxins. It is considered a dying-back neuropathy, or central-peripheral axonopathy, associated with secondary demyelination. Its existence was suspected by Charcot in 1880 (14) and Osler in 1892 (57). Since the introduction of hemodialysis and renal transplantation in early 1960s, uremic neuropathy has been thoroughly investigated. Before then there were only scant reports of an association between chronic renal failure and polyneuropathy, and its nature was unclear. In 1961, the cases of two young men with hereditary interstitial nephritis, nerve deafness, and polyneuropathy were reported (51). Asbury, Victor, and Adams described the clinical and pathological features in detail (04; 05). Dyck and colleagues established the current concept of uremic neuropathy based on nerve conduction studies and light and electron microscopy studies (20). Using quantitative histology, they demonstrated axonal shrinkage. Myelin sheaths appeared to be affected out of proportion to axons. Neuronal rather than axonal dysfunction appeared to result in reduced axonal diameter, myelin rearrangement, and finally, complete degeneration of the axon (20). Nielsen published numerous papers in clinical and electrophysiologic studies in the 1970s (53; 54). These descriptions have not changed significantly over time. The greatest strides have been in the documentation of the therapeutic effects of dialysis and renal transplantation on the peripheral neuropathy (72; 54; 29; 78).

Clinical manifestations

Presentation and course

There is a strong correlation between the severity of neuropathy and of the chronic renal insufficiency. Although most patients with chronic renal failure have subclinical evidence of a polyneuropathy, significant neuropathy generally occurs when the creatinine clearance falls below 5 mL/min, or the glomerular filtration rate falls below 20 mL/min (45).

Uremic neuropathy symptoms are insidious in onset and consist of a tingling and prickling sensation in the legs. Paresthesias are usually the earliest symptom. Numbness and burning sensation were observed in the distal lower limbs in 48.2% of patients and in the distal upper limbs in 3.6% of patients with uremic neuropathy (81). Hyperalgesia is common. Pruritus affects many patients with end-stage renal disease and may be related to both somatic and autonomic neuropathy (82). Weakness and atrophy will follow the sensory symptoms. As disease progresses, symptoms move proximally and also involve the arms. Muscle cramps and restless legs syndrome occur in 67% of uremic patients but may be independent of neuropathy (53). Patients report that crawling, prickling, and itching sensations in their legs are partially relieved by movement of the affected limb. Autonomic dysfunction is associated with postural hypotension, impaired sweating, sexual dysfunction, and alteration in gastric motility (08; 24; 65). Uremic optic neuropathy is rarely reported (27; 06; 63). Other cranial neuropathies were of cranial nerves III and VII and have presented as facial diplegia and ophthalmoplegia (35). A Guillain-Barre type of presentation with rapid progression to respiratory failure has been reported. Generalized limb weakness develops over days or weeks with imbalance, numbness, and diminished reflexes (47; 64; 61). Mononeuropathies in the form of compressive neuropathy can occur in the median nerve at wrist, in the ulnar nerve at the elbow, or in the peroneal nerve at the fibular head. Already dysfunctional peripheral nerves may be susceptible to local compression. The connective tissues and tendons surrounding the carpal tunnel may contain amyloid deposits (15). Carpal tunnel syndrome may also present distal to forearm arteriovenous fistulas because of distal ischemia (25).

Physical examination reveals impaired vibratory perception and absent deep tendon reflexes in 93% of patients. Pinprick sensation in a glove and stocking distribution was impaired in 16%, and muscular weakness and wasting were observed in 14% (53). Paradoxical heat sensation was found in the foot in 42%, compared to less than 10% in normal controls. Paradoxical heat sensation probably results from lowering of heat pain threshold (80). Autonomic dysfunction is demonstrated as postural hypotension and abnormal Valsalva maneuver. Cranial nerve involvement is rare; transient nystagmus, miosis, heterophoria, and facial asymmetry can occur (23). Focal weakness, sensory loss, and Phalen or Tinel signs at compression sites may be found in the median, ulnar, or peroneal nerve distribution.

Prognosis and complications

The prognosis in untreated uremic polyneuropathy is poor, as it often progresses to a disabling sensorimotor neuropathy. Untreated, its course resembles the cases in the original reports from the 1960s. Later patient series describe patients after renal transplantation or undergoing various forms of hemodialysis. With intermittent hemo- or peritoneal dialysis the clinical manifestations of neuropathy generally stabilize or improve slowly over time. Those with mild disease may recover peripheral nerve function completely, whereas more severely affected individuals recover incompletely, and some may continue to progress despite treatment. The prognosis after renal transplantation is more favorable, with excellent recovery of peripheral nerve function, especially in those without coexistent systemic illnesses such as diabetes (10; 54). Complications of uremic neuropathy are progressive disability including falls, which can result in severe fractures and subdural hematomas.

Clinical vignette

A 35-year-old woman noted leg numbness and weakness over the previous 2 years. Her medical history was notable for chronic glomerulonephritis, complicated by progressive renal failure over the previous 6 years. A neurologic examination revealed moderate wasting and weakness of all muscles below the knees. Vibratory and pinprick sensation were diminished below the knees. Deep tendon reflexes were intact in the arms, reduced at the knees, and absent at the ankles. Her gait was slightly unstable. She had undergone weekly hemodialysis for the past 3 years. Nerve conduction studies and EMG revealed a generalized sensorimotor polyneuropathy with moderate slowing of conduction velocities and denervation in muscles of the distal legs. Laboratory studies were notable for a creatinine clearance of 4 mL/min. There was no evidence of diabetes. She underwent a successful cadaveric renal transplantation. Over the next 6 months, leg sensation and strength slowly improved.

Biological basis

Etiology and pathogenesis

The etiology of uremic neuropathy remains unclear. Today, most authorities believe the neuropathy is secondary to toxin or metabolite accumulation that cannot be excreted by the nonfunctioning kidneys. In addition, malnutrition and arterial stiffness are significantly associated with small fiber neuropathy in patients undergoing hemodialysis (43). The nature of the toxic substances in uremia is also unknown. Several candidates have been proposed over the years, including small water-soluble compounds (guanidine, asymmetric dimethylarginine, creatinine, purines, oxalate, phosphorus, urea, kynurenine), middle molecules, advanced glycosylated end products (glycation), parathyroid hormone, oxidation products, beta-endorphin, methionine-enkephalin, beta-lipotropin, granulocyte inhibiting proteins I and II, degranulation–inhibiting protein, adrenomedullin, beta-2-microglobulin, complement factor D, and protein-bound compounds (homocysteine, Indoles, 3-Carboxy-4-methyl-5-propyl-2-furanpropionic acid, hippuric acid, indoxyl sulfate, p-cresol, polyamines) (18; 62; 59). An etiologic role for chronic hyperkalemia in uremic neuropathy has been suggested (38; 40; 42; 41). In patients with diabetic kidney disease, neuropathy was significantly more common versus other chronic kidney diseases or type II diabetes (p <  0.05); nerve excitability was more severely affected with increasing serum K+ (p <  0.01) (30).

Among these uremic toxins, the middle molecule hypothesis (75; 48) has gained the greatest attention. Because middle molecules with molecular weights in the range of 300 daltons to 2000 daltons are more difficult to remove with dialysis than small molecules, such as blood urea nitrogen and creatinine, which pass easily through dialysis membranes, these middle molecules may in some way be responsible for the neuropathy (19). Advanced glycosylated end products and parathyroid hormone are generally recognized as major uremic toxins (62). Bolton and colleagues postulated advanced glycosylated end products, which result from enzymatic reactions between glucose and proteins, as playing a role in uremic neuropathy (11). They noted that three of four patients who had been switched from conventional to high-flux hemodialysis, which removes advanced glycosylated end products, had clinical improvement in strength. Myoinositol, a precursor of phosphoinositide, is rapidly metabolized in neural membranes. It is abnormally elevated in chronic renal failure, poorly eliminated by hemodialysis, but excreted by renal cortex of successfully transplanted kidney (09).

The mechanism of uremic neuropathy, however, is poorly understood. Fraser and Arieff postulated that neurotoxic compounds deplete energy supplies in the axon by inhibiting nerve fiber enzymes required for energy production (23). Although all neuronal perikarya would be similarly affected by a toxic assault, the long axons would be the first to degenerate, as the longer the axon, the greater the metabolic load that the perikaryon bears (69). Axonal energy deprivation might be especially critical at nodes of Ranvier, which have higher energy demands for impulse conduction and axonal transport. Nielsen hypothesized that peripheral nerve dysfunction is related to an interference with axon membrane function and inhibition of sodium potassium activated ATPase by toxic factors in uremic serum (53). Bolton postulated that membrane dysfunction occurs at the perineurium, which functions as a diffusion barrier between interstitial fluid and nerve or within the endoneurium, which acts as barrier between blood and nerve. As a result, uremic toxins might enter the endoneural space at either site and cause not only direct nerve damage but also water and electrolyte shifts with expansion or retraction of this space (09). In two separate studies, axonal membrane properties were investigated by measuring nerve excitability in chronic renal failure patients before, during, and after hemodialysis (38; 42; 41). The authors suggested that motor and sensory axons in uremic patients were depolarized before dialysis and that hyperkalemia was primarily responsible for uremic depolarization; this process could contribute to the development of neuropathy.

In uremic neuropathy, the pathologic features are severe axonal degeneration in the most distal nerve trunks with secondary segmental demyelination. Dyck and colleagues found that the number of myelinated fibers at the mid-calf level was about half of normal, and only one third of normal at the ankle. In transverse electron microscope sections, most of the myelinated fibers of the uremic nerve had a normal appearance except for irregularities of the myelin sheath, such as splitting of the myelin lamellae and separation of axolemma from compact myelin (20). Muscle biopsy revealed fiber-type grouping from chronic denervation and reinnervation. Muscle was severely denervated in Guillain-Barré-type neuropathy. In advanced cases, electron microscopy revealed necrosis of myofibers, Z-band streaming, and aggregation of glycogen (16).

Diagnostic workup

The presence of a uremic peripheral neuropathy is established by medical history, neurologic examination, and electrophysiologic studies.

Laboratory findings. There are no specific features of neuropathy in chronic renal failure. Other metabolic disorders, neurotoxins, or inflammatory disorders may occur in association with chronic renal failure. Other causes of neuropathies should be ruled out by lab tests, including diabetes, vitamin deficiencies, thyroid dysfunction, inflammatory disorders, and toxins. The cerebrospinal fluid may show a moderately elevated protein, usually less than 100 mg/dL in about half the patients, whereas cell count and glucose are normal. Although the cerebrospinal fluid protein can be elevated in uremic patients without neuropathy, it is more likely to be elevated in patients with neuropathy.

Electrophysiologic evaluation. Nerve conduction study is a sensitive test for diagnosis of neuropathy in uremic patients. The most commonly involved nerves are the sural, ulnar sensory, median sensory, peroneal, and tibial (33). Sensory and motor nerve conduction velocities are reduced. Prolonged distal latencies are due to involvement of distal nerve segments; reduced compound action potential amplitudes are due mainly to reduced density of large, myelinated motor and sensory fibers. Prolongation of tibial and peroneal F-wave latencies and of H-reflexes is typical of patients with chronic renal failure (58; 36; 55). Distal denervation is often seen on needle exam, although at times it may be minimal or absent (12). Electrical amplitudes improve after dialysis, which is consistent with a pathogenic role of toxic substances and suggests that some features of uremic neuropathy are functional, not structural (50). Stosovic and colleagues reported that motor nerve conduction velocity predicted mortality in patients with uremic neuropathy (70). In compressive mononeuropathies, the conduction velocity will be slowed across the compression site. Carpal tunnel syndrome is common in the presence of uremic neuropathy. In patients with end-stage kidney disease, the frequency of carpal tunnel syndrome was 15% with routine nerve conduction studies and 25% with median-versus-ulnar comparison studies (66). Among the median-ulnar comparison, lumbrical-interossei comparison was most sensitive. Guillain-Barré–type neuropathy in chronic renal failure has moderate to severe conduction slowing, and conduction block may occur. Small fiber dysfunction was found in 32% of hemodialysis patients by cutaneous silent period measurement (17). Testing of autonomic function, including R-R interval and sympathetic skin responses, may be abnormal, even in patients without clinically evident autonomic dysfunction (24; 65). Esophageal manometry has been used to study subclinical manifestation of autonomic neuropathy in uremia. Eleven out of 16 patients were reported to show abnormal motility in the lower two thirds of the esophageal body (67).

Ultrasound. Sonographic alterations of peripheral nerve cross-sectional areas were demonstrated in diabetic kidney disease (31).

Management

Supportive measures are discussed in Peripheral neuropathies: supportive measures and rehabilitation.

Treatment of uremic neuropathy with dialysis and vitamin supplements is unsatisfactory, whereas renal transplantation in early-stage uremic neuropathy produces a favorable outcome.

Bolton concluded that modern methods of managing renal failure have decreased the incidence of uremic neuropathy (09). Chronic intermittent peritoneal dialysis or hemodialysis are both effective in stabilizing or improving some peripheral nerve function in patients with chronic renal failure, especially those with mild symptoms. By electrophysiologic evaluation, the frequency of peripheral neuropathy and carpal tunnel syndrome remained stable for more than 5 years of peritoneal dialysis (07). The incidence of uremic neuropathy may be lower with peritoneal dialysis than with hemodialysis because of peritoneal dialysis’ higher capacity for middle molecule removal (22). In a study, patients on peritoneal dialysis had more normal nerve excitability than those in the hemodialysis group despite similar duration of dialysis (03). In the process of hemodialysis, some previously inactive axons recover due to removal of toxic substances. Paresthesias may improve rapidly when dialysis begins, but other symptoms persist (74). The dialysis regimen can be optimized in a variety of ways, including changing the type of dialyzer or dialysis membrane (73; 75). Low weight gain between sessions, a low ultrafiltration rate, and peritoneal dialysis may improve autonomic symptoms (44; 24). Chronic hemodialysis may stabilize the neuropathy in most patients. However, the course of the neuropathy cannot be improved with certainty by simply manipulating the dialysis schedule (21; 09). The achievement of normokalemia has been suggested as a priority in the treatment of uremic patients (42; 41). The emergency of optic neuropathy must be addressed aggressively, with a regimen that includes dialysis, correction of anemia and hypotension, and corticosteroids (76; 63). Diabetes management in patients with diabetic kidney disease is important to reduce the severity of peripheral neuropathy (49).

Biotin is a low molecular weight coenzyme loosely bound to serum proteins, which may be removed during dialysis. A dose of 10 mg biotin three times a day was recommended in a series of nine patients whose mental function, sensory symptoms, and gait improved after 3 months of treatment (77). In addition, it was found that biotin counteracts the inhibitory effect of uremic plasma on microtubule formation in vitro (13). The use of vitamin B6 is controversial because although neuropathy symptoms may improve, it may be more toxic in uremia (56; 46).

Subcutaneous injection of erythropoietin has been used to treat anemia in patients with renal failure. In a study of 22 subjects with chronic renal failure and subclinical polyneuropathy, 15 completed a 5-month course of erythropoietin 80 units/kg per week (28). Compared with pretreatment nerve conduction studies, the motor nerve conduction velocities of the median, peroneal, and tibial nerves improved significantly (p< 0.05). Compound muscle action potentials of the median nerve were also increased significantly (p=0.01). However, there was no improvement in sensory nerve amplitude or velocity. No significant correlation was found between the increase in hemoglobin and the improvement in polyneuropathy.

Paresthesias can be treated as usual with anticonvulsants or tricyclic or other antidepressants. Please refer to the MedLink Neurology article “Neuropathic pain: treatment.” Gabapentin is frequently used, with the dose adjusted to the renal function or timing of dialysis. In the author’s experience, however, gabapentin can be titrated up cautiously, with the final dose dictated by efficacy and side effects. Because gabapentin is excreted only via the kidneys, it can be administered as a single dose after dialysis in the anuric patient. Venlafaxine is an antidepressant that is metabolized in liver; it has been reported to resolve burning and painful sensations in the feet and is well tolerated (79).

High-tone external muscle stimulation (HTEMS) therapy was investigated in 28 patients with chronic hemodialysis with neuropathy who received HTEMS for 1 hour during hemodialysis three times weekly for 12 weeks (71). In 64% general well-being improved, in 61% physical capacity increased, and in 57% the feeling of cold feet decreased. Ulnar NCVs improved in 19 patients. HTEMS also benefited physical and social functions and pain (39).

If the neuropathy continues to worsen, renal transplantation can be considered (60). Improvement was reported for all patients following the procedure (54). Paresthesias disappeared over 1 to 3 months in mild cases. Nerve conduction velocity rapidly improved after successful transplantation. The sympathetic and parasympathetic autonomic dysfunction is reversed as early as 3 to 6 months after transplantation. Improvement of erectile dysfunction was also reported (32). Its benefit for neuropathy is less with coexisting conditions such as diabetes. Optimization of comorbidities and avoidance of neurotoxic agents is of utmost importance.

Other neuropathy supportive measures are discussed in MedLink neurology article “Rehabilitation of peripheral nerve diseases.”

References

01: Abd El Naby SA, Bahbah WA, Kasemy ZA, Mahmoud AA. Neurophysiological and neuroradiological changes in children with chronic kidney disease. Front Pediatr 2020;8:570708. PMID 33313023
02: Aggarwal AK, Sood S, Jain D, Kaverappa V, Yadav S. Evaluation of spectrum of peripheral neuropathy in predialysis patients with chronic kidney disease. Ren Fail 2013;35(10);1323-9. PMID 23964701
03: Arnold R, Pussell BA, Kiernan MC, Kruihnan AV. Comparative study to evaluate the effects of peritoneal and hemodialysis on peripheral nerve function. Muscle Nerve 2016;54(1):58-64. PMID 26660121
04: Asbury AK, Victor M, Adams RD. Uremic polyneuropathy. Trans Amer Neurol Ass 1962;87:100-2.
05: Asbury AK, Victor M, Adams RD. Uremic polyneuropathy. Arch Neurol 1963;8:413-28. PMID 13965111
06: Basile C, Addabbo G, Montanaro A. Anterior ischemic optic neuropathy and dialysis: role of hypotension and anemia. J Nephrol 2001;14(5):420-3. PMID 11730278
07: Basturk T, Koc Y, Kayalar AO, et al. Frequency of polyneuropathy in patients on long term peritoneal dialysis treatment. J Clin Diagn Res 2017;11(6):OC37-40. PMID 28764223
08: Bellinghieri G, Santoro D, Lo Forti B, Mallamace A, De Santo RM, Savica V. Erectile dysfunction in uremic dialysis patients: diagnostic evaluation in the sildenafil era. Am J Kidney Dis 2001;38(Suppl 1):S115-7. PMID 11576935
09: Bolton CF. Peripheral neuropathies associated with chronic renal failure. Can J Neurol Sci 1980;7(2):89-96. PMID 6250697
10: Bolton CF, Baltzan MA, Baltzan RG. Effects of renal transplantation on uremic neuropathy. N Engl J Med 1971;284:1170-5. PMID 4324615
11: Bolton CF, McKeown MJ, Chen R, Toth B, Remtulla H. Subacute uremic and diabetic polyneuropathy. Muscle Nerve 1997a;20(1):59-64. PMID 8995584
12: Bolton CF, Remtulla H, Toth B, et al. Distinctive electrophysiologic features of denervated muscle in uremic patients. J Clin Neurophysiol 1997b;14(6):539-42. PMID 9458061
13: Braguer D, Gallice P, Yatzidis H, Berland Y, Crevat A. Restoration by biotin of the in vitro microtubule formation inhibited by uremic toxins. Nephron 1991;57(2):192-6. PMID 2020347
14: Charcot JM. Lecons sur les maladies du systeme nerveux. XVI Des paraplegies urinares. 3rd ed. Paris, 1880:295.
15: Charra B, Calemard E. Carpal tunnel syndrome, shoulder pain and amyloid deposits in long term hemodialysis. Proc Eur Dial Transplant Assoc 1984;21:291.
16: Chen QT. Uremic neuropathy. [Chinese]. Zhonghua Shen Jing Jing Shen Ke Za Zhi 1989;22(1):35-6, 62-3. PMID 2553356
17: Denislic M, Tiric-Campara M, Resic H, et al. A neurophysiological study of large- and small-diameter nerve fibers in the hands of hemodialysis patients. Int Urol Nephrol 2015;47(11):1879-87. PMID 26433886
18: Dhondt A, Vanholder R, Van Biesen W, Lameire N. The removal of uremic toxins. Kidney Int Suppl 2000;76:S47-59. PMID 10936799
19: Djukanovic LJ, Mimic-Oka JI, Potic JB. The effects of hemodialysis with different membranes on middle molecules and uremic neuropathy. Int J Artif Organs 1989;12:11-9. PMID 2538398
20: Dyck PJ, Johnson WJ, Lambert EH, O'Brien PC. Segmental demyelination secondary to axonal degeneration in uremic neuropathy. Mayo Clin Proc 1971;46:400-31. PMID 4326086
21: Dyck PJ, Johnson WJ, Lambert EH, O'Brien PC, Daube JR, Oviatt KF. Comparison of symptoms, chemistry, and nerve function to assess adequacy of hemodialysis. Neurology 1979;29:1361-8. PMID 573380
22: Fenton SS, Schaubel DE, Desmeules M, et al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am J Kidney Dis 1997;30:334-42. PMID 9292560
23: Fraser CL, Arieff AI. Nervous system complications in uremia. Ann Intern Med 1988;109(2):143-53. PMID 2837930
24: Galetta F, Cupisti A, Franzoni F, et al. Changes in heart rate variability in chronic uremic patients during ultrafiltration and hemodialysis. Blood Purif 2001;19:395-400. PMID 11574736
25: Gousheh J, Iranpour A. Association between carpal tunnel syndrome and arteriovenous fistula in hemodialysis patients. Plast Reconstr Surg 2005;116:508-13. PMID 16079682
26: Green RM. CIDP masquerading as uremic polyneuropathy. Neurology 1992;42(6):1248-9. PMID 1603354
27: Haider S, Astbury NJ, Hamilton DV. Optic neuropathy in uremic patients on dialysis. Eye 1993;7:148-51. PMID 8325406
28: Hassan K, Simri W, Rubenchik I, et al. Effect of erythropoietin therapy on polyneuropathy in predialytic patients. J Nephrol 2003;16(1):121-5. PMID 12649543
29: Hupperts RM, Leunissen KM, van Hooff JP, Lodder J. Recovery of uremic polyneuropathy after renal transplantation. Clin Neurol Neurosurg 1990;92:87-9. PMID 2154362
30: Issar T, Arnold R, Kwai NCG, et al. Relative contributions of diabetes and chronic kidney disease to neuropathy development in diabetic nephropathy patients. Clin Neurophysiol 2019;130(11):2088-95. PMID 31541986
31: Issar T, Walker S, Arnold R, Poynten AM, Endre ZH, Krishnan AV. Peripheral nerve morphology and intraneural blood flow in chronic kidney disease with and without diabetes. Muscle Nerve 2022;65(5):603-7. PMID 35119701
32: Jabali SS, Saleem ZSM, Mohammed AA, Mahmood NM. Erectile dysfunction pre and post kidney transplant recipients in Duhok city; cross sectional study. Ann Med Surg (Lond) 2020;55:107-10. PMID 32477507
33: Jasti DB, Mallipeddi S, Anumolu A, B V, V S, Kolli S. A clinical and electrophysiological study of peripheral neuropathies in predialysis and dialysis patients: our experience from South India. J Assoc Physicians India 2018;66(6):31-7. PMID 31331132
34: Jedras M, Zakrzewska-Pniewska B, Gellert R, Debowska M, Wojtaszek E, Wardyn K. Uremic neuropathy is more frequent in male patients. [Polish]. Pol Arch Med Wewn 2001;105:391-8. PMID 11865591
35: Jegatheswaran J, Torres C, Clark E. Uremic cranial neuropathy. Kidney Int 2018;93(4):1021. PMID 29571444
36: Jurcic D, Bago J, Eljuga D, et al. Features of uremic neuropathy in long-term dialysis. Coll Antropol 1998;22(1):119-25. PMID 10097427
37: Jurcic D, Bilić A, Schwarz D, et al. Clinical course of uremic neuropathy in long-term hemodialysis. Coll Antropol 2008;32:771-5. PMID 18982751
38: Kiernan MC, Walters RJ, Andersen KV, Taube D, Murray NM, Bostock H. Nerve excitability changes in chronic renal failure indicate membrane depolarization due to hyperkalaemia. Brain 2002;125:1366-78. PMID 12023325
39: Klassen A, Racasan S, Gherman-Caprioara M, et al. High-tone external muscle stimulation in endstage renal disease: effects on quality of life in patients with peripheral neuropathy. Clin Nephrol 2013;79 Suppl 1:S28-33. PMID 23249530
40: Krishnan AV, Phoon RK, Pussell BA, Charlesworth JA, Bostock H, Kiernan MC. Altered motor nerve excitability in end-stage kidney disease. Brain 2005;128:2164-74. PMID 15947058
41: Krishnan AV, Phoon RK, Pussell BA, Charlesworth JA, Bostock H, Kiernan MC. Neuropathy, axonal Na+/K+ pump function and activity-dependent excitability changes in end-stage kidney disease. Clin Neurophysiol 2006b;117:992-9. PMID 16516547
42: Krishnan AV, Phoon RK, Pussell BA, Charlesworth JA, Kiernan MC. Sensory nerve excitability and neuropathy in end stage kidney disease. J Neurol Neurosurg Psychiatry 2006a;77:548-51. PMID 16543542
43: Kuo MC, Huang JC, Wu PY, et al. Associations of small fiber neuropathy with geriatric nutritional risk index and arterial stiffness in hemodialysis. Dis Markers 2020;2020:1694218. PMID 32509039
44: Laaksonen S, Voipio-Pulkki L, Erkinjuntti M, Asola M, Falck B. Does dialysis therapy improve autonomic and peripheral nervous system abnormalities in chronic uraemia. J Int Med 2000;248:21-6. PMID 10947877
45: Layzer RB. Neuromuscular manifestations of systemic disease. Philadelphia: FA Davis, 1985:283-96.
46: Levine S, Saltzman A. Pyridoxine (vitamin B6) toxicity: enhancement by uremia in rats. Food Chem Toxicol 2002;40:1449-51. PMID 12387307
47: Lynch PG, Yuill GM, Nicholson JA. Acute polyneuropathy complicating chronic renal failure. Nephron 1971;8(3):278-88. PMID 5155280
48: Malberti F, Surian M, Farina M, et al. Effect of hemodialysis and hemodiafiltration on uremic neuropathy. Blood Purification 1991;9:285-95. PMID 1668062
49: Mallipeddi S, Jasti DB, Apparao A, Vengamma B, Sivakumar V, Kolli S. A clinical and electrophysiological study of peripheral neuropathies in peritoneal dialysis patients: our experience from rural South India. Saudi J Kidney Dis Transpl 2018;29(5):1139-49. PMID 30381511
50: Mansouri B, Adybeig B, Rayegani M, Yasami S, Behshad V. Uremic neuropathy and the analysis of electrophysiological changes. Electromyogr Clin Neurophysiol 2001;41:107-15. PMID 11284054
51: Marin OS, Tyler HR. Hereditary interstitial nephritis associated with polyneuropathy. Neurology 1961;11:999-1005. PMID 14469843
52: Marra TR. Proximal vs distal nerve conduction measurements in uremic neuropathy. Electromyogr Clin Neurophysiol 1988;28(7-8):439-43. PMID 2854787
53: Nielsen VK. The peripheral nerve function in chronic renal failure: a survey. Acta Med Scand 1974a;(suppl)573:6-32.
54: Nielsen VK. The peripheral nerve function in chronic renal failure. VIII. Recovery after renal transplantation. Clinical aspects. Acta Med Scand 1974b;195:163-70. PMID 4595251
55: Ogura T, Makinodan A, Kubo T, Hayashida T, Hirasawa Y. Electrophysiological course of uraemic neuropathy in haemodialysis patients. Postgrad Med J 2001;77:451-4. PMID 11423596
56: Okada H, Moriwaki K, Kanno Y, et al. Vitamin B6 supplementation can improve peripheral polyneuropathy in patients with chronic renal failure on high-flux haemodialysis and human recombinant erythropoietin. Nephrol Dial Transplant 2000;15:1410-13. PMID 10978399
57: Osler W. The principles and practice of medicine. 7th ed. London: Appleton, 1892:684, 699.
58: Panayiotopoulos CP, Lagos G. Tibial nerve H-reflex and F-wave studies in patients with uremic neuropathy. Muscle Nerve 1980;3(5):423-6. PMID 6252459
59: Pawlak D, Tankiewicz A, Buczko W. Kynurenine and its metabolites in the rat with experimental renal insufficiency. J Physiol Pharmacol 2001;52:755-66. PMID 11785771
60: Pirzada NA, Morgenlander JC. Peripheral neuropathy in patients with chronic renal failure. A treatable source of discomfort and disability. Postgrad Med 1997;102(4):249-50. PMID 9336610
61: Priti K, Ranwa B. Acute fulminant uremic neuropathy following coronary angiography mimicking Guillain-Barre syndrome. Heart Views 2017;18(2):62-3. PMID 28706599
62: Raj DS, Choudhury D, Welbourne TC, Levi M. Advanced glycation end products: a nephrologist's perspective. Am J Kidney Dis 2000;35:365-80. PMID 10692262
63: Raja N, Rajagopalan A, Arunachalam J, Prasath A, Durai R, Rajendran M. Uremic optic neuropathy: a potentially reversible complication of chronic kidney disease. Case Rep Nephrol Dial 2022;12(1):38-43. PMID 35611027
64: Ropper AH. Accelerated neuropathy of renal failure. Arch Neurol 1993;50:536-9. PMID 8387770
65: Savica V, Musolino R, Di Leo R, Santoro D, Vita G, Bellinghieri G. Autonomic dysfunction in uremia. Am J Kidney Dis 2001;38(Suppl 1):S118-21. PMID 11576936
66: Shende VS, Sharma RD, Pawar SM, Waghmare SN. A study of median nerve entrapment neuropathy at wrist in uremic patients. Indian J Nephrol 2015;25(4):229-33. PMID 26199474
67: Siamopoulos KC, Tsianos EV, Dardamanis M, Berecos C. Esophageal dysfunction in chronic hemodialysis patients. Nephron 1990;55(4):389-93. PMID 2392192
68: Sonbhadra A, Reddy BVC, Saini AG, et al. Peripheral neuropathy in children with chronic kidney disease: are we looking enough? Ann Indian Acad Neurol 2022;25(3):389-93. PMID 35936645
69: Spencer PS, Sabri MI, Schaumburg HH, Moore CL. Does a defect of energy metabolism in the nerve fiber underlie axonal degeneration in polyneuropathies. Ann Neurol 1979;5(6):501-7. PMID 89830
70: Stosovic M, Nikolic A, Stanojevic M, et al. Nerve conduction studies and prediction of mortality in hemodialysis patients. Ren Fail 2008;30:695-9. PMID 18704818
71: Strempska B, Bilinska M, Weyde W, et al. The effect of high-tone external muscle stimulation on symptoms and electrophysiological parameters of uremic peripheral neuropathy. Clin Nephrol 2013;79 Suppl 1:S24-7. PMID 23249529
72: Taylor N, Halar EM, Tenckhoff H, Marchioro TL, Masock AJ. Effects of renal transplantation on motor nerve conduction velocity. Arch Phys Med Rehabil 1972;53:227-31. PMID 4337700
73: Tegner R, Lindholm B. Uremic polyneuropathy: different effects of hemodialysis and continuous ambulatory peritoneal dialysis. Acta Med Scand 1985;218:409-16. PMID 4083083
74: Thomas PK. Screening for peripheral neuropathy in patients treated by chronic hemodialysis. Muscle Nerve 1978;1(5):396-9. PMID 233738
75: Violante F, Lorenzi S, Fusello M. Uremic neuropathy: clinical and neurophysiological investigation of dialysis patients using different chemical membranes. Eur Neurol 1985;24(6):398-404. PMID 4065159
76: Winkelmayer WC, Eigner M, Berger O, Grisold W, Leithner C. Optic neuropathy in uremia: an interdisciplinary emergency. Am J Kidney Dis 2001;37:74-80. PMID 11228200
77: Yatzidis H, Koutsicos D, Agroyannis B, Papastephanidis C, Francos-Plemenos M, Delatola Z. Biotin in the management of uremic neurologic disorders. Nephron 1984;36(3):183-6. PMID 6322032
78: Yildiz A, Sever MS, Demirel S, et al. Improvement of uremic autonomic dysfunction after renal transplantation: a heart rate variability study. Nephron 1998;80(1):57-60. PMID 9730704
79: Yilmaz ME, Kadiroglu AK, Kara IH, Dikici S. Venlafaxine in the treatment of painful peripheral diabetic neuropathy in a uremic patient undergoing hemodialysis. MedGenMed 2002;4(3):23. PMID 12466766
80: Yosipovitch G, Yarnitsky D, Mermelstein V, et al. Paradoxical heat sensation in uremic polyneuropathy. Muscle Nerve 1995;18(7):768-71. PMID 7783767
81: Yu XZ, Lu S, Gou W, et al. Assessment of the characteristics and quality of life of patients with uremic peripheral neuropathy. Clin Nephrol 2017;87(3):134-9. PMID 28102815
82: Zakrzewska-Pniewska B, Jedras M. Is pruritus in chronic uremic patients related to peripheral somatic and autonomic neuropathy. Study by R-R interval variation test (RRIV) and by sympathetic skin response (SSR). Neurophysiol Clin 2001;31:181-93. PMID 11488229

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Yi Pan MD PhD

Dr. Pan of VA St. Louis Health Care System has no relevant financial relationships to disclose.
See Profile
Florian P Thomas MD MA PhD MS

Dr. Thomas of Hackensack Meridian School of Medicine had no relevant financial relationships to disclose.
See Profile

Editor

Louis H Weimer MD

Dr. Weimer of Columbia University has no relevant financial relationships to disclose.
See Profile

Former Authors

Barbara Shapiro MD PhD (original author)

Patient Profile

Age range of presentation: 6 to 65+ years
Sex preponderance: male>female, <2:1

The issue of gender differences in uremic neuropathy and its symptoms remains unclear (Jedras et al 2001).
Heredity: heredity may be a factor
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Uremic neuropathy

Associated Disorders

Diabetic neuropathy
Diseases cause chronic renal failure
Inflammatory demyelinating polyneuropathy
Nutritional deficiency
Restless legs syndrome
- Toxic neuropathy

Differential Diagnosis

systemic disorders
toxins
diabetes mellitus
nutritional deficiency
multiple myeloma
- primary amyloidosis
- vasculitides
- connective tissue disorder
- polyarteritis nodosa
- systemic lupus erythematosus
- nitrofurantoin
- colchicine
- alcohol abuse
- chronic inflammatory demyelinating polyneuropathy
- prominent demyelination

Uremic neuropathy …

Uremic neuropathy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Neuropathies associated with cytomegalovirus infection

Clinical evaluation of peripheral neuropathies

Hypothyroidism

Monoclonal gammopathy of neurologic significance

Chronic inflammatory demyelinating polyradiculoneuropathy

Amyotrophic lateral sclerosis

Amiodarone neuropathy

Autoimmune autonomic neuropathy

Uremic neuropathy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Neuropathies associated with cytomegalovirus infection

Clinical evaluation of peripheral neuropathies

Hypothyroidism

Monoclonal gammopathy of neurologic significance

Chronic inflammatory demyelinating polyradiculoneuropathy

Amyotrophic lateral sclerosis

Amiodarone neuropathy

Autoimmune autonomic neuropathy

This is an article preview.
Start a Free Account
to access the full version.